Summary of opinion: Pepaxti, 17/09/2026 Positive
Summary of opinion: Pepaxti, 17/09/2026 Positive
Summary of opinion: Pepaxti, 17/09/2026 Positive
Programme of the 2026 annual meeting of the European network of paediatric research at EMA (EnprEMA)
Human medicines European public assessment report (EPAR): Nucala, mepolizumab, Date of authorisation: 01/12/2015, Revision: 29, Status: Authorised
Human medicines European public assessment report (EPAR): Avtozma, tocilizumab, Date of authorisation: 14/02/2025, Revision: 8, Status: Authorised
Summary of opinion: Enhertu, 17/09/2026 Positive
Quarterly System Demo - Q3 2026, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 17 September 2026, 09:00 (CEST) to 17 September 2026, 11:30 (CEST)
MedDRA important medical event terms list (IME) - version 29.1
User safety for pharmaceutical veterinary medicinal products - Scientific guideline
Organisation chart: Human Medicines
Draft guideline on user safety for pharmaceutical veterinary medicinal products - Revision 2